We present a pediatric case to highlight the clinical appearance and management of choroidal neovascularization in the setting of active toxoplasma retinochoroiditis (TRC). A 17-year-old female presented with 2 days of blurry vision in her left eye. Retinal examination demonstrated a pigmented chorioretinal lesion with associated subretinal fluid, vessel sheathing, and adjacent intraretinal hemorrhage. She was diagnosed with active choroidal neovascularization and successful treatment with bevacizumab revealed an underlying active toxoplasmosis lesion. Choroidal neovascularization may rarely present during an acute case of TRC. Dual therapy with anti-vascular endothelial growth factor antibody and anti-parasitic agents leads to improved visual outcomes.

Toxoplasma retinochoroiditis (TRC) accounts for a majority of posterior uveitis worldwide [1, 2]. Toxoplasmosis gondii has an affinity for nervous tissue, specifically the retinal ganglion cells in the eye [3]. TRC occurs in healthy children or young adults in 75% of cases, often during puberty [1, 4]. Various clinical presentations have been reported, including destructive active retinitis with associated vitritis [4]. Less commonly, retinal punctate lesions with subretinal exudate and minimal vitreous reaction occur in up to 3% of patients [4]. As a progressive and recurring necrotizing retinitis, TRC is associated with long-term vision-threatening complications including retinal detachment, glaucoma, and choroidal neovascular membrane (CNVM) [2]. While CNVM is a well-known late complication of TRC, there are few reports of CNVM during periods of acute infection and inflammation [5, 6]. We report the clinical presentation and management of a patient presenting with choroidal neovascularization which initially masked active TRC and was successfully treated with dual anti-VEGF and anti-parasitic therapy.

A 17-year-old previously healthy immunocompetent female presented with sudden onset distortion in vision of her left eye that she described as a “bicycle spoke” for 2 days. Her best-corrected visual acuity (BCVA) at presentation was 20/60 in the left eye with a superior nasal deficiency on confrontational visual fields. Anterior segment examination of the left eye was remarkable for 1+ cell in the anterior chamber. The BCVA for the right eye was 20/20, and the anterior and posterior segment exam was unremarkable. Fundus exam of the left eye demonstrated an inferotemporal pigmented chorioretinal lesion. There was a large area of subretinal fluid associated with the pigmented chorioretinal lesion. Subtle sheathing of the inferotemporal arterioles and venules and adjacent intraretinal hemorrhage were noted on biomicroscopic evaluation (Fig. 1a). Fluorescein angiography of the left eye demonstrated blocking early in the area of the pigmented chorioretinal lesion with late leakage and pooling (Fig. 1b, c). Optical coherence tomography (OCT) showed a focal area of retinal thinning inferotemporally with adjacent subretinal lesion and a large amount of subretinal fluid (Fig. 1d). Macular OCT demonstrated subfoveal tracking of fluid from inferotemporal macula and cystic intraretinal fluid centrally (Fig. 1e). Vitreous opacities were noted overlying the area of inferotemporal subretinal fluid as well as the optic nerve (Fig. 1d, e).

Fig. 1.

a Color fundus photograph demonstrating inferotemporal pigmented chorioretinal lesion (white arrow) with associated subretinal fluid (white star). Sheathing of the inferotemporal arterioles and venules (black arrows) and adjacent intraretinal hemorrhage (black star). b, c Fluorescein angiography demonstrating early blocking in the area of the pigmented chorioretinal lesion with late leakage and pooling. d OCT demonstrating a focal area of retinal thinning with adjacent subretinal lesion and a large amount of subretinal fluid. e Macular scan demonstrating subfoveal fluid. OCT, optical coherence tomography.

Fig. 1.

a Color fundus photograph demonstrating inferotemporal pigmented chorioretinal lesion (white arrow) with associated subretinal fluid (white star). Sheathing of the inferotemporal arterioles and venules (black arrows) and adjacent intraretinal hemorrhage (black star). b, c Fluorescein angiography demonstrating early blocking in the area of the pigmented chorioretinal lesion with late leakage and pooling. d OCT demonstrating a focal area of retinal thinning with adjacent subretinal lesion and a large amount of subretinal fluid. e Macular scan demonstrating subfoveal fluid. OCT, optical coherence tomography.

Close modal

The clinical and imaging findings were consistent with an active CNVM, and the patient was treated with an intravitreal injection of bevacizumab (1.25 mg/0.05 mL). She presented for follow-up 2 weeks after receiving the injection with floaters although vision was subjectively improved. Fundus examination 5 weeks after initial presentation demonstrated near complete resolution of subretinal fluid, no vitreous cell, and active retinochoroiditis adjacent to the old toxoplasmosis scar (Fig. 2a, b). Macular scan demonstrated resolution of subfoveal fluid (Fig. 2c). The rapid resolution of subretinal and intraretinal fluid following intravitreal anti-VEGF therapy confirmed the diagnosis of CNVM while revealing the TRC lesion. Given the concern for active TRC, she was treated with oral trimethoprim-sulfamethoxazole (800–160 mg) monotherapy daily for a period of 5 months and did not require additional bevacizumab injections. The patient was followed-up for a period of 5 months, with notable improvement in inflammation and a final BCVA of 20/20.

Fig. 2.

a Color fundus photograph 5 weeks after initial presentation demonstrating inferotemporal pigmented chorioretinal scar (white arrow) with improvement of subretinal fluid revealing active retinochoroiditis adjacent to the old toxoplasmosis scar. b OCT demonstrating active TRC lesion with overlying vitreous cell. c Macular scan demonstrating resolution of subfoveal fluid. *Image copyright holder is the Department of Ophthalmology and Visual Sciences at the University of Michigan W.K. Kellogg Eye Center. OCT, optical coherence tomography.

Fig. 2.

a Color fundus photograph 5 weeks after initial presentation demonstrating inferotemporal pigmented chorioretinal scar (white arrow) with improvement of subretinal fluid revealing active retinochoroiditis adjacent to the old toxoplasmosis scar. b OCT demonstrating active TRC lesion with overlying vitreous cell. c Macular scan demonstrating resolution of subfoveal fluid. *Image copyright holder is the Department of Ophthalmology and Visual Sciences at the University of Michigan W.K. Kellogg Eye Center. OCT, optical coherence tomography.

Close modal

Choroidal neovascularization associated with TRC was first described in 1969 by Friedmann and Knox [7] as a late complication of this parasitic infection. It has since been recognized as one of the most common late complications of TRC, occurring in up to 19% of patients within 26 years after initial diagnosis [8, 9]. There are few case reports, however, of CNVM during the acute infectious phase of TRC. Willerson et al. [10] described the first case of subretinal neovascularization in association with active TRC in 1977. A case report by Hegde et al. [5] cited 3 cases of coexisting CNVM with active TRC. All patients presented with subretinal hemorrhage adjacent to the pigmented lesion. One patient presented in their teenage years with history of bilateral ocular toxoplasmosis and unilateral CNVM with active TRC on presentation. The patients were treated with a combination of anti-VEGF, trimethoprim/sulfamethoxazole ,and oral corticosteroids, with resolution of the retinitis within 6 weeks and CNVM within 6–12 weeks [5]. Rishi et al. [11] presented another example of CNVM secondary to TRC in a teenager. The patient presented with history of bilateral ocular toxoplasmosis, with unilateral subfoveal CNVM and subretinal fluid adjacent to active TRC. The patient was managed with a combination of photodynamic therapy and intravitreal anti-VEGF injection after a period of 2 days, with resolution of CNVM within 8 weeks [11].

While late-onset CNVM presents adjacent to retinochoroidal scars in healed TRC, CNVM alongside active TRC may be seen anywhere within the active retinitis lesion [5, 11]. CNVM with active TRC seems to occur more commonly in younger patients with acquired toxoplasmosis, and may lead to vision loss, especially in cases of foveal involvement [11]. CNVM with active TRC typically presents with minimal vitritis, a yellow-white necrotizing retinitis lesion with adjacent subretinal hemorrhage, macular thickening, and subretinal fluid [5]. In contrast to the above case reports, our patient presented in adolescence with a unilateral pigmented chorioretinal lesion adjacent to CNVM with overlying vitritis and subretinal fluid. The extramacular location of TRC may have contributed to the delayed presentation of our patient, resulting in the concomitant presentation of a CNVM with significant activity.

The pathogenesis of CNVM associated with late TRC is thought to be attributed to the preferential selection of retinal microvascular endothelium by T. gondii tachyzoites [12]. By contrast, during the active phase of TRC, it has been postulated that ongoing retinitis impedes venous outflow leading to active vasoproliferation [5, 6]. It is hypothesized that some patients develop CNVM during active TRC due to the intense retinal inflammation causing a break in Bruch’s membrane and choriocapillaris [5].

It can be difficult to distinguish active infectious retinitis in the setting of a CNVM, as demonstrated in this case. The lack of vitritis on clinical examination and masking of active retinochoroiditis by the large amount of subretinal fluid in our patient concealed the underlying TRC. However, the acute infectious retinitis was revealed by the successful treatment of CNVM and resolution of subretinal fluid and implementation of anti-parasitic therapy led to a quick response and improvement of vision.

We present a rare pediatric case of choroidal neovascularization in the setting of active TRC. Choroidal neovascularization rarely presents in the setting of active TRC, especially in the pediatric population. A combination of anti-vascular endothelial growth factor antibody and anti-parasitic agents leads to significant improvement in visual acuity.

Written informed consent for patient information and images to be published was provided by the patient.

The authors have no conflicts of interest to declare.

The authors received no financial support for the research, authorship, and/or publication of this article.

C.G.B. was responsible for the conception and design of this project. N.S.K. and R.A.H. were responsible for data collection, data analysis, and interpretation. N.S.K. was responsible for drafting of the manuscript. R.A.H. and C.G.B. were responsible for critical revision of the article. Final approval of the version to be submitted for publication was performed by N.S.K., R.A.H., and C.G.B.

1.
Smith
JR
,
Cunningham
ET
 Jr
.
Atypical presentations of ocular toxoplasmosis
.
Curr Opin Ophthalmol
.
2002
Dec
;
13
(
6
):
387
92
.
[PubMed]
1040-8738
2.
Park
YH
,
Nam
HW
.
Clinical features and treatment of ocular toxoplasmosis
.
Korean J Parasitol
.
2013
Aug
;
51
(
4
):
393
9
.
[PubMed]
0023-4001
3.
Noble
KG
,
Carr
RE
.
Toxoplasma retinochoroiditis
.
Ophthalmology
.
1982
Nov
;
89
(
11
):
1289
90
.
[PubMed]
0161-6420
4.
Cotliar
AM
,
Friedman
AH
.
Subretinal neovascularisation in ocular toxoplasmosis
.
Br J Ophthalmol
.
1982
Aug
;
66
(
8
):
524
9
.
[PubMed]
0007-1161
5.
Hegde
S
,
Relhan
N
,
Pathengay
A
,
Bawdekar
A
,
Choudhury
H
,
Jindal
A
, et al.
Coexisting choroidal neovascularization and active retinochoroiditis-an uncommon presentation of ocular toxoplasmosis
.
J Ophthalmic Inflamm Infect
.
2015
Jul
;
5
(
1
):
22
.
[PubMed]
1869-5760
6.
Mushtaq
F
,
Ahmad
A
,
Qambar
F
,
Ahmad
A
,
Zehra
N
.
Primary Acquired Toxoplasma Retinochoroiditis: Choroidal Neovascular Membrane as an Early Complication
.
Cureus
.
2019
Feb
;
11
(
2
):
e4001
.
[PubMed]
2168-8184
7.
Friedmann
CT
,
Knox
DL
.
Variations in recurrent active toxoplasmic retinochoroiditis
.
Arch Ophthalmol
.
1969
Apr
;
81
(
4
):
481
93
.
[PubMed]
0003-9950
8.
Atmaca
LS
,
Simsek
T
,
Batioglu
F
.
Clinical features and prognosis in ocular toxoplasmosis
.
Jpn J Ophthalmol
.
2004
Jul-Aug
;
48
(
4
):
386
91
.
[PubMed]
0021-5155
9.
Skorska
I
,
Soubrane
G
,
Coscas
G
.
[Toxoplasmic choroiditis and subretinal neovessels]
.
J Fr Ophtalmol
.
1984
;
7
(
3
):
211
8
.
[PubMed]
0181-5512
10.
Willerson
D
 Jr
,
Aaberg
TM
,
Reeser
F
,
Meredith
TA
.
Unusual ocular presentation of acute toxoplasmosis
.
Br J Ophthalmol
.
1977
Nov
;
61
(
11
):
693
8
.
[PubMed]
0007-1161
11.
Rishi
P
,
Venkataraman
A
,
Rishi
E
.
Combination photodynamic therapy and bevacizumab for choroidal neovascularization associated with toxoplasmosis
.
Indian J Ophthalmol
.
2011
Jan-Feb
;
59
(
1
):
62
4
.
[PubMed]
0301-4738
12.
Smith
JR
,
Franc
DT
,
Carter
NS
,
Zamora
D
,
Planck
SR
,
Rosenbaum
JT
.
Susceptibility of retinal vascular endothelium to infection with Toxoplasma gondii tachyzoites
.
Invest Ophthalmol Vis Sci
.
2004
Apr
;
45
(
4
):
1157
61
.
[PubMed]
0146-0404
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.